Esketamine shows promise for treatment-resistant depression

An estimated one-third of patients with major depressive disorder have treatment-resistant depression (TRD), characterized by an inadequate response to two or more oral antidepressants (OADs).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup